The contribution of cytotoxic chemotherapy to the management of cancer.
暂无分享，去创建一个
[1] Graeme Morgan,et al. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. , 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).
[2] Dl Ball,et al. Clinical Practice Guidelines for the Prevention, Diagnosis and Management of Lung Cancer , 2004 .
[3] A. Szczepura. Healthcare outcomes: gemcitabine cost-effectiveness in the treatment of non-small cell lung cancer. , 2002, Lung cancer.
[4] R. Gelber,et al. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis , 2001, The Lancet.
[5] D. Coyle,et al. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. , 2000, Journal of the National Cancer Institute.
[6] J. Bourhis,et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data , 2000, The Lancet.
[7] Mike Clarke,et al. Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[8] M. Tattersall,et al. Long-term survival with advanced ovarian cancer: an analysis of 5-year survivors in the Australian trial comparing combination versus sequential chlorambucil and cisplatin therapy. , 1992, Gynecologic oncology.